STA-1474 sodium

STA-1474 (0.001-1 μM; 1-7 days) sodium potently inhibits the proliferation of D17, OSA2, OSA8 and MG63 osteosarcoma cell lines, with IC₅₀ values ranging from 0.011 μM to 0.043 μM, and exhibits selectivity for OSA cells relative to normal canine osteoblasts (IC₅₀ = 0.072 μM)^[1].
STA-1474 (0.1 μM; 24-48 h, followed by drug-free incubation for 2-6 h) sodium mediates time-dependent and reversible downregulation of p-STAT3 in MG63 and D17 osteosarcoma cell lines, which confirms that this effect directly results from HSP90 inhibition rather than non-specific toxicity^[1].
STA-1474 (0.01-1 μM; 24-48 h) sodium induces dose-dependent apoptosis in OSA8 and MG63 osteosarcoma cell lines, but does not affect apoptosis in normal canine osteoblasts; it activates caspase 3/7 in a dose-dependent manner in D17 and OSA8 osteosarcoma cell lines, and induces dose-dependent PARP cleavage in D17, OSA2, OSA8 and MG63 osteosarcoma cell lines; it downregulates HSP90 client proteins (p-Met, total Met, p-Akt, total Akt, p-STAT3), and induces upregulation of stress response proteins HSP70 and HSP90^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.